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ABSTRACT 
 
The tumor microenvironment is complex and often includes matricellular proteins and 
regions of hypoxia, which can promote stem and progenitor properties that regulate cancer 
cell biology. We hypothesized that hypoxia and CCN2 would promote notochord progenitor-
like characteristics in human chordoma (U-CH1) cells, and assessed cell phenotype using 
Real-time qPCR and in vitro functional assays. We found the expression of CCN family 
members CCN1, CCN2, CCN3 and CCN5 in U-CH1 cells. We demonstrate that hypoxia and 
CCN2 promoted progenitor-like characteristics specific to the notochordal tissue of origin. 
Specifically, hypoxia had the greatest ability to promote progenitor characteristics (increase 
in notochord markers T, CD24, FOXA1, ACAN and CA12, sphere formation, cell growth and 
fewer vacuolated cells) and the effects of CCN2 were more pronounced under normoxia than 
hypoxia. This study highlights the importance of the tumor microenvironment and how these 
components can be used to regulate human chordoma behaviour. 
 
 
 
Keywords: chordoma, notochord, hypoxia, connective tissue growth factor, 
microenvironment 
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1.1 Overview of chordoma 
1.1.1 Basic understanding of chordoma 
 Chordomas are rare, malignant and locally invasive tumors that occur most 
commonly at the base of the skull (32%) and sacrococcygeal region (29%), and less 
frequently in cervical, thoracic and lumbar vertebrae 1,2. The cancer typically affects one 
in one million people each year in the United States with the median age of diagnosis 
being 49 for skull-based chordomas and 69 for sacral-based chordomas 1.  The median 
age of survival for patients affected with chordomas is 6 years and the tumors have a high 
rate of recurrence 3. Studies report that males are more commonly affected than females, 
with the ratio of males to females with chordoma being approximately 1.6 to 1. The 
cancer has also been reported to less frequently affect African-American individuals 
compared to Caucasians 1. Chordomas are low-grade tumors that have a high rate of 
recurrence and are capable of metastasizing to areas including the lungs, liver, bone and 
skin 4.  
  
 The clinical presentation of chordoma varies depending on the anatomical region 
affected. Patients affected by skull-based chordomas often present with headaches, neck 
pain or double vision whereas patients with sacral-based chordomas have changes in 
bowel/bladder function, pain, numbness or weakness in the legs and arms 5.  A major 
setback for patients remains the limited treatment options, as the tumors are often 
resistant to traditional chemotherapy and radiation therapy 6-7. As a result, surgical 
resection is the major form of treatment, however complete resection is often difficult to 
achieve due to the invasive behaviour and proximity of tumors to the spinal cord 6,8. 
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 Currently, there are a limited number of studies that examine the biology of these 
tumors and their malignant transformation from the pre-cancerous cell of origin 
(notochord cells). This paradigm highlights the importance of gaining a basic 
understanding of this cancer, as this could contribute to the development of more 
effective treatment options for patients. 
 
1.1.2 Development of the notochord and vertebral column  
 The vertebral column is comprised of vertebral bone separated by intervertebral 
discs. During formation of the vertebral column, the notochord is the embryonic structure 
that acts as the primitive axis of the embryo and induces patterning of surrounding tissues 
9. Using murine models, it has been shown that the notochord elongates at embryonic day 
(E) 7.5 from a structure known as the node, which originates from the mesoderm 10. In 
humans, complete formation of the notochord occurs at E20 (Figure 1.1A); at this time 
the notochord is surrounded by a structure called the notochord sheath, which helps 
maintain the rod-like structure of the notochord 11-12. At the end of embryonic week 5, 
segmented blocks of paraxial mesoderm called somites divide and encircle the notochord. 
These somites segment and produce alternating condensed and non-condensed regions 
that will give rise to the annulus fibrosus and vertebral bodies, respectively 13-14. The 
notochord enlarges between the vertebral bodies to form the future nucleus pulposus, 
which is located in the middle of the intervertebral disc 13,15 (Figure 1.1B). In humans, 
the notochord cells are thought to disappear a few years after birth. There remains 
controversy surrounding whether notochord cells develop into chondrocyte-like nucleus 
pulposus cells or if they die and are replaced by cells that migrate into the nucleus   
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Figure 1.1. Illustration of the notochord that forms the nucleus pulposus in humans. 
(A) Shows the formation of the notochord at E20 surrounded by somites. (B) Shows the 
notochord derived nucleus pulposus in the middle of the intervertebral disc surrounded by 
the outer annulus fibrosus. 
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pulposus from the inner annulus fibrosus or cartilage endplate  13-16. Recent studies using 
lineage tracing in the murine model have established that all cells of the mature nucleus 
pulposus are derived from the embryonic notochord 16,19. 
 
One of the factors involved in notogenesis is T, the founding member of the T-
box family of transcription factors. T is expressed in the notochord and to a lesser extent 
in the nucleus pulposus, and is critical to notochord formation 19,20. The complete loss of 
T in mice has been shown to cause embryonic lethality at E10.0 due to impaired axial 
development and allantoic defects 21,22. In comparison, knockdown of T in mice resulted 
in notochord formation but the cells were not able to differentiate and mice exhibited 
axial skeletal defects 23. T has also been shown to be highly expressed in nucleus 
pulposus tissue in rats at 12 months of age compared to rats at 21 months of age, where 
there was a significant decrease in expression 24. In humans, DNA sequence analysis has 
correlated a missense mutation in the T locus to vertebral malformations 25.  
 
 Aggrecan (ACAN) is a proteoglycan that is expressed in a variety of tissues 
including the notochord and notochord sheath 26. In addition, ACAN is expressed in the 
extracellular matrix of normal (non-degenerate) human nucleus pulposus disc tissue and 
confers water bearing capacity to the disc due to osmotic pressure provided by its 
chondroitin sulphate chains 27, 28. SOX9 is a transcription factor that is a member of the 
SOX (Sry-type high mobility group box) family of genes and that has been shown to 
increase expression from the aggrecan gene promoter in human chondrocyte cells 29. 
Interestingly, this effect was found to be cell-type dependent, as SOX9 enhancement of 
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ACAN promoter activity was not found in osteoblast-like osteosarcoma cells. In addition, 
SOX9 is important for notochord development as SOX9-null mice do not form a 
continuous notochord, with regions in the cervical and thoracic sections disrupted at 
E10.5 30. After E10.5, these mice displayed a progressive rostral to caudal loss of the 
notochord. SOX9 is also expressed in normal (non-degenerate) human nucleus pulposus 
tissues 28.   
 
 In addition to SOX9, the transcription factors SOX5 and SOX6 and forkhead box 
A1 and A2 (FOXA1 and FOXA1) are important for notochord development. Both SOX5 
and SOX6 are expressed in murine notochord cells and their expression decreases as 
notochord cells differentiate into mature nucleus pulposus cells 31. SOX5-/-;SOX6-/- mice 
lack formation of the notochord sheath. In addition, the notochord cells of these mice 
underwent apoptosis and were not able to form nucleus pulposi, although the inner 
annulus was present 31. FOXA1 is expressed in the notochord and floor plate, whereas 
FOXA2 is expressed in the node, notochord and floorplate 32. Mice lacking both FOXA1 
and FOXA2 show deformed nucleus pulposi that were small and compressed at E17.5. 
These mice also demonstrated abnormal notochord sheath formation and the lack of a 
visible notochord at the forelimb level 33. 
 
 Although in the field of spine research there is a general lack of notochord and 
nucleus pulposus-specific markers, heat stable antigen CD24 is a cell surface receptor 
that has been shown to be expressed in the notochord of rats and nucleus pulposus of 
humans 34,35. In addition, carbonic anhydrase XII (CA12) has been shown to be expressed 
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exclusively in the notochord in mice and the nucleus pulposus of young human subjects 
while its expression decreases in older subjects 32-34. 
 
1.1.3 Notochordal cell and the origin of chordoma 
 Our lab and others have demonstrated that notochord cells act as tissue-specific 
progenitor cells within the murine intervertebral disc, through a traditional fate mapping 
study 19, 16. Using a novel NotoCre/+ mouse crossed with a LacZ reporter mouse, where 
Cre recombinase was expressed specifically in the node and posterior notochord through 
targeting of the Noto locus, this study permanently labeled cells of notochordal origin 19. 
This genetic strategy demonstrated that all cells of mature nucleus pulposus were derived 
from the embryonic notochord and also identified small clusters of notochord cells within 
the vertebrae of skeletally mature mice (Figure 1.2). In the study, the presence of 
notochord remnants (i.e. benign notochord cell tumors) was reported in at least one 
vertebrae in >90% of skeletally mature mice. A similar study that used fate-mapping 
analysis to examine cells of notochord origin with ShhCre mice also noted the presence of 
notochord remnant cells in all mice examined along the entire length of the vertebral 
column 16. 
 
 Similar to findings in the mouse model, a study using 100 human cadavers noted 
the presence of benign notochord cell tumors in 20% of the cadavers  39. The anatomical 
distribution of the tumors was similar to that of chordomas (11.5% clivus, 5% cervical 
vertebrae, 2% lumbar vertebrae 12% sacro-coccygeal vertebrae). Another study used 82  
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Figure 1.2. Localization of notochord-derived cells in skeletally mature mice 
(postnatal day 100). Linage tracing of notochord-derived cells using notochord-specific 
Cre mouse (NotoCRE) crossed with the Rosa26 LacZ reporter demonstrates the localization 
of notochordal cells to the nucleus pulposus of the intervertebral discs (white arrow 
heads) as well as clusters of notochordal remnants within the vertebral bone (black dotted 
box). (Reproduced with permission from McCann et al. Dis Model Mech., 2012) 
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human cadavers and found that 7.3% of cadavers contained benign notochord cell tumors 
40. The age of cadavers with these tumors ranged from 40-70 years old; however, another 
study found that these benign tumors could be found in patients as young as 14 years old 
41. Since the occurrence of chordoma is rare (1 in 1 million cases per year), it has been 
suggested that these benign notochord cell tumors lay dormant throughout a person’s 
lifetime unless stimulated by other factors. Chordomas are believed to arise from these 
benign notochord cell tumors, based on histological association in three separate patient 
cases. In the first case, a resected chordoma from the coccyx was found adjacent to an 
benign notochord cell tumor in a 57-year old patient 42. In the next two cases, the 
presence of an incipient chordoma was found alongside benign notochord cell tumors 43. 
Histologically, the chordomas appeared as cords of tumor cells that contained a myxoid 
(mucoid) matrix with eccentrically located nuclei and physaliferous cells 43. The major 
difference between chordomas and benign notochord cell tumors is the lack of a mucoid 
matrix and nuclear atypia 44. Furthermore, the benign notochord tumors and chordomas 
stained positively for epithelial marker antigen (EMA), vimentin, cytokeratin and S-100, 
which are also markers of the embryonic notochord 45–47. 
 
1.1.4 Human chordoma cell lines 
 An overarching issue associated with the use of chordoma cell lines for research 
are concerns that many of the chordoma cell lines generated from primary tumors do not 
accurately represent human chordomas 48. For example, the CCL3 49, CCL4 50, GB60 51  
and CM319 52 cell lines lack genetic alterations typical of human cancers and lack copy 
number aberrations that have been associated with chordomas, such as losses on 
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chromosome 3p, or cell morphology that is not consistent with the typical physaliferous 
morphology of chordoma cells 48. The human chordoma cell lines U-CH1 53, U-CH2 48, 
MUG-Chor1 54 and JHC7 6 are generally considered the most representative models of 
chordoma.  
 
 The current study was conducted using U-CH1, a cell-line derived from a 46-year 
old male with a recurrent sacral chordoma 53. When cultured in vitro, the cell line is a 
heterogenous population containing both vacuolated “physaliferous” cells and small non-
vacuolated cells (Figure 1.3). U-CH1 cells express S-100, vimentin, EMA, CD24 and 
cytokeratin, which are typical markers of chordomas 39,43-53. In addition, gene expression 
analysis has shown that U-CH1 expresses T 10-fold higher than the U-CH2 cell line 53. 
U-CH1 has been shown to have a loss of the PTEN tumor suppressor gene, consistent 
with chordoma tumors 48. U-CH1 was directly compared to the parent tumor from which 
cells were isolated, which confirmed similar physaliferous cells and positive staining for 
cytokeratin 53. U-CH1 has also been used to create a mouse xenograft model of chordoma 
following injection of cells into the NOD/SCID/interleukin 2 receptor-null mouse 55. The 
study demonstrated that the U-CH1 xenograft was morphologically similar to chordoma 
and that cells expressed T. 
 
1.2 The tumor microenvironment and role of matricellular proteins 
1.2.1 Basic overview of the CCN family members 
 The CCN family is comprised of six matricellular proteins (CCN1, CCN2, CCN3, 
CCN4, CCN5 and CCN6) that bind to cell-surface receptors, components of the  
11 
 
 
 
Figure 1.3. Morphological appearance of U-CH1 human chordoma cell line. 
Representative phase contrast image of UCH-1 cells maintained in monolayer culture 
(P39), as previously described. White arrow indicates a vacuolated (“physaliferous”) cell 
and arrowhead indicates a non-vacuolated cell. (Scale bar = 250 µm) 
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extracellular matrix, proteases and signaling molecules such as cytokines and hormones 
56-57. As a result, these proteins have a variety of functions that regulate cell adhesion, 
mitosis, apoptosis, migration and extracellular matrix production in a variety of different 
cell types 58. Members of the CCN family play roles in development, wound healing and 
diseases including cancer. 
  
 CCN proteins are composed of four modules: the insulin-like growth factor 
binding protein domain (module 1), a Von Willebrand factor domain (module II), a 
thrombospondin-homology domain (module III) and a cysteine knot, heparin-binding 
domain (module IV). The one exception is CCN5 which lacks module IV 59 (Figure 1.4). 
Domains II and III are linked by hinge regions that can be cleaved by proteases 58. The 
CCN proteins share 40-60% of their amino acid sequences and have a gene structure 
consisting of five exons and four introns 58. 
 
1.2.2 Role of CCN proteins in cancer 
 The tumor microenvironment is composed of a variety of different cell types 
including cancer cells, stromal fibroblasts, endothelial cells, as well as secreted proteins, 
oxygen levels, matricellular proteins and components of the extracellular matrix 60 
(Figure 1.5). CCN proteins contribute to the regulation of various aspects of tumor 
progression such as epithelial-mesenchymal transition (EMT), angiogenesis, cell 
proliferation, cell migration and extracellular matrix degradation. 
 
 CCN1 has been implicated in prostate cancer, glioma, pancreatic cancer and  
13 
 
 
 
Figure 1.4. Schematic illustration depicting the structure of CCN family proteins. 
CCN family members share a secretory signal peptide (SP) and four domains: (1) IGF-
binding domain, (2) a von Willebrand type C domain (VWC), (3) a thrombospondin-1 
domain (TSP-1) and (4) a cysteine knot domain. The exception is CCN5, which lacks a 
cysteine knot domain. There is a hinge region between domains II and III that is 
susceptible to cleavage. (Reproduced with permission from Leask et al. J Cell Sci., 2006) 
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Figure 1.5. Example of a tumor microenvironment. Schematic representation 
depicting components of the tumor microenvironment including tumor cells, blood 
vessels, immune cells, extracellular matrix components, matricellular proteins and 
regions of hypoxia and normoxia. 
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breast cancer. In prostate carcinoma cells, CCN1 has been shown to enhance cell 
adhesion through α6β1 and α6β4 integrin binding and heparan sulfate proteoglycan binding 
and also to increase cell proliferation 61-62. CCN1 was detected in pancreatic cancer cells, 
and blocking of CCN1 inhibited cell migration 63. Studies in breast cancer cell lines show 
that CCN1 expression is correlated to increased invasiveness, anchorage-independent 
growth, tumor progression and VEGF secretion through α5β3 integrin binding 66-67. 
 
 CCN2 has been shown to play a role in a variety of cancers including lung, 
gallbladder, leukemia, breast and pancreatic cancer. In lung adenocarcinoma cells, CCN2 
has been shown to induce anoikis, which in turn suppresses metastasis 66. Studies using 
gallbladder cancer cell lines demonstrated that CCN2 knockdown reduces cell viability, 
colony formation and anchorage-independent growth 67. A study using five leukemia cell   
lines showed that CCN2 is expressed in all of the cell lines and that silencing of this gene 
resulted in suppressed cell growth 68. In breast cancer, overexpression of CCN2 in MCF-
7 cells resulted in reduced cell proliferation, increased migration and increased 
angiogenesis 69. An in vivo mouse model of bone metastasis using breast cancer cells 
(MDA231) showed that blocking of CCN2 resulted in reduced osteolytic bone metastasis 
and decreased tumor proliferation and migration 70. Lastly, overexpression of CCN2 in 
pancreatic cancer cells significantly increased colony formation 71. Studies using 
recombinant CCN2 (rCCN2) have found that this protein can both promote and reduce 
the ability of cells to differentiate. For example, a study using hepatic progenitor cells 
found that rCCN2 peptide promoted hepatic differentiation 72. Another study found that 
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treatment of mesenchymal stem cells with full length rCCN2 peptide reduced their ability 
to differentiate 73.  
 
 CCN3 has been implicated in prostate and breast cancer, and also 
chondrosarcoma. Studies have shown that breast cancer patients with bone metastasis 
show elevated CCN3 in their tumors 70. Furthermore, CCN3 knockdown inhibits cell 
migration, tumor growth in bone and bone metastasis in an in vivo mouse model of 
prostate cancer 71. CCN3 is also expressed in bone metastases from patients with breast 
cancer 76. A study demonstrated that overexpression of CCN3 in breast cancer cells 
(66cl4) increased bone metastases when cells were injected into the left cardiac ventricle 
of mice 76. Mice with ectopic expression of CCN3 were found to have increased bone 
metastases (31%) compared to control mice (14%). CCN3 has also been shown to have a 
role in glioma, where overexpression of CCN3 in glioma cells demonstrated an anti-
proliferative effect 77. Furthermore, studies using the JJ012 human chondrosarcoma cell 
line found that CCN3 expression promoted cell migration 78.  
 
 CCN5 has been shown to play a role in breast and pancreatic cancers. A study 
using an invasive breast cancer cell line (MDA-MB-231) showed that overexpression of 
CCN5 reduced cell proliferation and invasiveness, and that the loss of CCN5 expression 
promoted breast cancer progression 81-82. A study using human pancreatic 
adenocarcinoma cell lines showed that overexpression of CCN5 promoted epithelial-
mesenchymal transition 79. 
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 To date, there are no studies examining the role of CCN proteins in chordoma. 
Thus far, there is evidence suggesting that CCN2 may play a role in chordoma 
pathogenesis through its interaction with T, which is amplified in sporadic chordomas 
and duplicated in familial chordomas 57,82. A recent study examined the T transcriptional 
network in UCH-1 chordoma cells and identified CCN2 as a direct downstream target 82. 
 
1.2.3 Role of CCN2 in notochordal cells 
 Studies have shown that CCN2 is enriched in the notochord and nucleus pulposus 
of mice (Figure 1.6) 85-86 and is secreted by notochord cells in the nucleus pulposus of 
non-chondrodystrophic dogs 85. In zebrafish, knockdown of Ccn2 resulted in disrupted 
notochord development, including tail buds that failed to elongate 86. Recently, our lab 
generated a mouse strain with targeted deletion of CCN2 in notochord and notochord-
derived cells 83. This study found that loss of CCN2 in notochord-derived cells disrupted 
extracellular matrix composition within the IVD at postnatal day 1, with decreased levels 
of ACAN and collagen type II alpha I (COL2A1) in the putative nucleus pulposus. These 
mice also displayed accelerated age-related disc degeneration in 12 and 17 month old 
mice compared to wild-type controls. Studies in humans have shown that CCN2 is more 
highly expressed in degenerated IVDs than normal IVDs, leading to a debate regarding 
the role played by CCN2 in accelerating disc degeneration or contributing to a reparative 
tissue response 89-90.  
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Figure 1.6. CCN2 localization in notochord and notochord-derived tissues of the 
murine intervertebral disc. Representative images demonstrating localization of CCN2 
in mice. (A) Depicts CCN2 mRNA localization by in situ hybridization in the posterior 
aspect of the embryo as E12.5 (indicated by the black arrow; Scale bar = 500 µm). 
(Matthew McCann, unpublished data) (B) Immunolocalization of CCN2 protein in the 
newly formed intervertebral disc at postnatal day 1. (Scale bar = 50 µm) (Reproduced 
with permission from Bedore et al., Arthritis & Rheum., 2013).  
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1.3 The tumor microenvironment and role of hypoxia 
1.3.1 The effects of hypoxia in cancer 
As previously described, tumor microenvironments are highly complex and are often 
marked by oxygen tension levels distinct from those of surrounding healthy tissues. The 
normal oxygen level in tissues is approximately 20% O2 (normoxia), which is oxygen in 
air at normal atmospheric pressure 89. Solid tumors often create hypoxic environments 
(usually between 1-3% O2 but can vary depending on the type of tumor) due to a limited 
oxygen supply 89. Hypoxic conditions result from inadequate oxygen supply to the tumor, 
which is usually caused by limited ability for blood to carry oxygen, reduced tissue 
perfusion and inconsistencies in blood flow diffusion 90. Normally, these conditions 
would be harmful to cells but cancer cells adapt to these conditions by undergoing 
genetic changes promoting survival 91.  
 
 In hypoxic conditions, cells often show increased levels of hypoxia-inducible 
factor 1-alpha (HIF1-α). HIF1-α belongs to a family of HIF proteins that respond to low 
oxygen conditions and are involved in regulating many pathways, such as its interaction 
with the Notch signaling network 92. Under normoxic conditions, the α subunit of the 
HIF1-α protein is rapidly degraded through hydroxylation of two key proline residues in 
the oxygen-dependent degradation domain 93. However, under hypoxic conditions HIF1-
α becomes stabilized and heterodimerizes with the aryl hydrocarbon receptor nuclear 
translocator (ARNT) in the nucleus. Upon heterodimerization, HIF1-α binds to hypoxia-
response elements within the genome, inducing the expression of many hypoxia-response 
genes. The activated genes can be involved in a variety of processes including cell 
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proliferation, angiogenesis, metabolism, migration and apoptosis 91. For example, 
vascular endothelial growth factor (VEGF) and glucose transporter 1 (GLUT1) are 
immediate downstream targets of HIF1-α involved in angiogenesis and glycolysis 94.  
 
1.3.2 Effects of hypoxia on stem and progenitor stem cell populations 
 The effect of hypoxia on stem cell and progenitor cell populations is an area of 
active investigation, as hypoxia has been shown to have different effects on the 
differentiation of stem and progenitor cells. In general, progenitor cells are early 
descendants of stem cells that can differentiate to form one or more kinds of cells but are 
more limited in the kinds of cells they can become and cannot self-renew indefinitely. 
 
 Murine bone marrow cells have been shown to have an increased number of 
progenitor cells and a higher stem cell potential in hypoxia (1% O2) compared to cells 
maintained in normoxia for 8 days 95. The cells maintained under hypoxia also 
demonstrated increased colony formation compared to cells in normoxia. Hematopoietic 
progenitor cells also show similar responses to hypoxic environments, with a reported 
four-fold expansion in the number of CD34+ cells (a marker for primitive blood and bone 
marrow-derived progenitor cells) in hypoxia (1% O2) compared to normoxia 96. In 
contrast, hypoxia (5% O2) has been shown to promote cell differentiation in neuronal 
stem cells 97. Interestingly, differentiation of human mesenchymal stem cells into 
osteoblastic or adipogenic lineages was not affected by culture in hypoxia; however, cells 
demonstrated a nine-fold increase in proliferation under hypoxia (2% O2) compared to 
normoxia 98.  
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 The effect of hypoxia on cancer stem cell and progenitor populations is still an 
active area of research. Studies conducted using glioma and glioblastoma cells 
demonstrated that hypoxia (1-2% O2) promoted a more stem-like phenotype, with the 
upregulation of the pluripotency markers OCT4, NANOG and the cancer stem cell 
marker CD133 99–101. These cells were able to form spheres faster and demonstrated 
reduced cell differentiation compared to cells in normoxia. In addition, ovarian cancer 
cells (ES-2 and OVCAR-3) have been shown to upregulate cancer stem cell markers 
CD44 and CD133 under hypoxia and also demonstrate increased sphere formation in 
vitro 102. In addition, hypoxia has been shown to have different effects on cell migration, 
where it has increased migration of glioblastoma cells (U87) and decreased the migration 
of human prostate cancer cells compared to normoxia 103, 104. 
 
 To date, no studies have examined the effects of hypoxia on the maintenance on a 
cancer stem cell or progenitor cell population in chordomas. A previous report assessed 
the expression of stem cell markers on UCH-1 cells and reported that a subset of cells 
were positive for CD90 (11.82%), CD105 (5.66%), CD166 (4.76%), CD73 (0.46%), 
CD45 (8.2%), CD34 (2.66%) or CD133 (2.6%) 105. In another study, primary human 
chordoma tumor samples were stained with stem cell surface marker CD44, which was 
detected in 50% (8 out of 16) chordoma patient tumor samples106. One limitation to the 
claim that CD44 and CD133 mark chordoma cancer stem cells is the lack of functional 
studies isolating or characterizing CD44+ or CD133+ populations using standard 
xenograft models. The MUG-Chor1 human chordoma cell line was assessed for aldehyde 
dehydrogenase (ALDH) activity and reported a small (0.3%) population of ALDHhigh 
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cells 107. ALDH is a cystolic enzyme responsible for retinoic acid metabolism and cellular 
self-protection from oxidative damage, and has been found in cancer stem populations in 
various cancers such as breast and pancreatic cancer 108, 113–116.  
 
1.3.3 Effects of hypoxia on chordoma cells 
 Determining the effects of hypoxia on chordoma cell biology is important, as a 
study using positron electron tomography on a sacrococcygeal chordoma demonstrated 
that a large volume of the chordoma tumor is hypoxic 117. There are currently a limited 
number of studies investigating the effects of hypoxia on chordoma cell biology. One 
study reported that chordoma cells (CH8, GB60, U-CH1) cultured in hypoxic conditions 
(5% O2) showed no differences in cell proliferation when compared to cells grown in 
normoxia over 7 days 118. However, another study used a primary human chordoma cell 
line and found that culture in hypoxia (5% O2) increased cell proliferation compared to 
cells maintained in normoxia over 5 days 50. 
 
1.3.4 Effects of hypoxia on the nucleus pulposus 
 The intervertebral disc is an avascular structure that demonstrates a range of 
oxygen concentrations across the intervertebral disc. The central nucleus pulposus (NP) is 
a hypoxic environment and as a result, the NP cells have developed mechanisms to 
maintain their function and survival in this environment. For example, HIF1-α expression 
is higher in the NP compared to the annulus fibrosus or cartilage endplate tissues of the 
disc 119. Studies using primary NP cells from rat, human and sheep reported that HIF1-α 
protein levels were not significantly increased when cells were placed under hypoxic (2% 
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O2) conditions compared to normoxic conditions 119. The authors therefore suggested that 
NP cells maintain high HIF1-α levels, regardless of the oxygen environment. 
 
 Furthermore, studies reported that exposure to hypoxia increased levels of ACAN 
gene expression in NP cells isolated from rat (2% O2) 120, bovine (5% O2) 121 and human 
(3.5% O2) 122 samples and increased levels of COL2A1 and SOX9 in the human samples 
compared to cells maintained in normoxia. Human NP cells also show increased 
proliferation in hypoxic conditions 122. Hypoxia has also been shown to have a role in 
preventing cell apoptosis, as rat NP cells grown in hypoxic conditions survive serum 
starvation better (12-15% of cells underwent apoptosis) than cells in normoxia (35-40% 
of cells underwent apoptosis) 123. Lastly, hypoxia has been shown to influence CCN2 
expression in rat NP cells 124. Cells cultured in hypoxia showed a significant decrease in 
CCN2 gene expression and protein expression. The overexpression of HIF1-α in these 
cells resulted in suppression of CCN2 promoter activity, suggesting that hypoxia 
decreases CCN2 expression and promoter activity in a HIF1-α-dependent manner. This is 
in contrast to chondrocytic cells, which showed the addition of rCCN2 increased HIF1-α 
mRNA and protein levels 125. 
 
 The effects of hypoxia and CCN2 on human chordoma cells remain largely 
unknown. As previously mentioned, studies have demonstrated that a large volume of 
chordoma is hypoxic and that CCN2 is a direct downstream target of the known 
chordoma marker brachyury (T), whose mutations are associated with sporadic and 
familial chordomas 34-35. In the current study, we sought to better understand the role 
24 
 
played by the tumor microenvironment in regulating chordoma cell biology by 
specifically investigating the effects of hypoxia and CCN2 on the regulation of human 
chordoma (U-CH1) cells, as they have both been implicated in regulating cancer cell 
biology and stem and progenitor properties in other cell types. 
 
1.4 Rationale, hypothesis and objectives 
Rationale: We sought to investigate microenvironmental regulation of human chordoma 
cells (U-CH1). We chose to specifically study the effects of CCN2 and hypoxia, as 
studies have shown that these are important factors in the tumor microenvironment that 
may regulate chordoma pathogenesis. 
 
Hypothesis: Hypoxic conditions and/or increased levels of CCN2 will alter the 
phenotype and functional properties of human chordoma cells, promoting progenitor-like 
characteristics specific to the notochordal tissue of origin. 
 
Objectives: In order to test our hypothesis, we developed two specific objectives: 
1) To examine the effect of hypoxia on human U-CH1 chordoma cells. 
2) To examine the effect of CCN2 and the additive effects of CCN2 and hypoxia on human 
U-CH1 chordoma cells. 
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2.1 Introduction 
 Chordomas are rare, malignant and locally invasive tumors that originate in bones 
of the skull and spine and are thought to arise from cellular remnants of the embryonic 
notochord. These tumors occur most commonly at the base of the skull (32%) and 
sacrococcygeal region (29%), and less frequently in cervical, thoracic and lumbar 
vertebrae 1-2. The cancer typically affects one in one million people each year in the 
United States, with the median age of diagnosis being 49 for skull-based chordomas and 
69 for sacral-based chordomas 1. 
 
 During embryonic development, notochord cells act as tissue-specific progenitor 
cells that give rise to the nucleus pulposus of the intervertebral disc 3-4; however, during 
spine formation some of these notochord cells get trapped within bone and are referred to 
as benign notochord remnants. Since these benign notochord remnants give rise to 
chordomas 3-9, it can be suggested that factors associated with the regulation of 
embryonic notochord development may likewise be associated with the development of 
chordomas. For example, studies have demonstrated that brachyury (T), a factor 
necessary for the formation and maintenance of the notochord 8-9, is amplified in sporadic 
chordomas and duplicated in familial chordomas10-11. In addition to T, there are various 
other factors that are involved in normal notochord development such as SOX (sry-type 
high mobility group box) family members SOX5, SOX6 and SOX9. Studies have shown 
that all of these members are involved in notochord development and that SOX9 is also 
expressed in the nucleus pulposus 12-13. In addition, aggrecan (ACAN) and forkhead box 
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protein A1 (FOXA1) are also involved in the formation of the notochord 14-15, and ACAN 
is also a critical component of the nucleus pulposus 16.  
 
 There are a limited number of studies that examine the effects of the tumor 
microenvironment on human chordoma cell biology. Two important components that are 
often found in the tumor microenvironment are hypoxia and matricellular proteins 
including CCN proteins. Hypoxic conditions (usually between 1-3% O2 but vary 
depending on the type of tumor 17) often result from inadequate oxygen supply to the 
tumor, which can be caused by low oxygen tension in arterial blood, limited ability for 
blood to carry oxygen, reduced tissue perfusion or inconsistencies in blood flow diffusion 
18. Normally, these conditions would be detrimental to cells but cancer cells adapt to 
these conditions; for example, under hypoxia prostate cancer cells show increased cell 
proliferation19, and prostate 19, breast 20 and colon 21 cancer cells display increased 
migration compared to cells cultured under normoxia. In addition, studies have shown 
that hypoxia can promote stem and progenitor cell properties in various cancers including 
glioma and glioblastoma 22 and ovarian cancer cells 23.  
 
 Connective tissue growth factor (CCN2) is part of the CCN family of 
matricellular proteins. CCN2 is expressed in many tissues including the notochord 24 and 
nucleus pulposus 25 and is important in notochord development 26. CCN2 also has a role 
in cancer cell biology and has been shown to promote cell proliferation, colony 
formation, migration and angiogenesis in a cell type-specific manner 27-28. CCN2 has also 
been shown to modulate stem and progenitor cell properties; mesenchymal stem cells 
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treated with recombinant CCN2 (rCCN2) demonstrated reduced differentiation, whereas 
the addition of rCCN2 to hepatic progenitor cells promoted hepatocytic differentiation 29-
30.  
 
 The specific effects of hypoxia and CCN2 on chordoma cells are largely 
unknown. Studies have demonstrated that a large volume of chordoma tumors are 
hypoxic 31 and that CCN2 is a direct downstream target of T in chordoma 32. In this 
study, we sought to better understand the role of the tumor microenvironment by 
specifically investigating the effects of hypoxia and CCN2 on the regulation of human 
chordoma cells using the U-CH1 cell line 33. Through characterization of gene expression 
and functional analyses, we demonstrate that exposure of U-CH1 cells to hypoxic 
conditions or increased levels of CCN2 promoted progenitor-like characteristics specific 
to the notochordal tissue of origin. Interestingly, exposure of chordoma cells to hypoxia 
induced more pronounced changes in in vitro cell behavior than did exposure of cells to 
CCN2. We found an additive effect when CCN2 and hypoxia were combined in the cell 
microenvironment on the expression of a subset of notochord progenitor markers. 
  
2.2 Materials and Methods 
2.2.1 Cell lines and cell culture 
 All experiments were conducted using the previously characterized U-CH1 
chordoma cell line 33 obtained from Dr. Michael Kelley (Duke University, North 
Carolina, United States). Cells were maintained using previously established protocols in 
IMDM/RPMI (4:1) (Invitrogen, Life Technologies) supplemented with 10% fetal bovine 
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serum (Invitrogen, Life Technologies) (chordoma media) on 0.1% gelatin coated cell 
culture plates. U-CH1 cells were maintained until monolayer cultures reached 80-90% 
confluency, and cells were enzymatically dissociated using 0.25% Trypsin (Gibco, Life 
Technologies) and plated at a ratio of 1:3-1:6 for cell expansion. 
 
 Recombinant human CCN2 (PHG0286, Life Technologies) was resuspended in 
0.1% bovine serum albumin in phosphate buffered saline (PBS) (17513F, Lonza); this 
11.2 kDa amino acid peptide fragment corresponds to amino acids 253-349 of the full 
length human CCN2 and contains the cysteine knot domain (rCCN2domain4). U-CH1 cells 
were treated with rCCN2domain4 at 50, 100 or 200 ng/mL in IMDM/RPMI (4:1) with 5% 
FBS. 
 
 All cell culture was carried out at 37°C in a humidified atmosphere of 5% CO2 in 
either normoxic (20% O2) or hypoxic (2% O2) conditions. Cells were maintained for at 
least 1-2 passages in either normoxia or hypoxia before experiments were performed. 
 
2.2.2 Immunocytochemistry 
 Monolayer cultures of U-CH1 cells (70-80% confluence) were fixed in 4% 
paraformaldehyde (37°C) for 10 minutes. Fixed cells were washed three times in 0.2% 
Triton X-100 in PBS (PBST) and then blocked using 5% species-specific serum in PBST 
for 30 minutes at room temperatures. Cells were then incubated overnight at 4° C in 5% 
species-specific serum in PBST containing primary antibodies against human CCN1 
(1:200; sc13100, Santa Cruz Biotechnology), CCN2 (1:200; sc14939, Santa Cruz 
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Biotechnology), CCN3 (1:200); AF1976, R&D Systems), brachyury (1:400; sc17743, 
Santa Cruz Biotechnology) or HIF1-α (1:200; sc13515, Santa Cruz Biotechnology). 
Following incubation, cells were washed three times with PBST and incubated with 
fluorescence conjugated species-specific secondary antibodies (donkey anti-goat IgG 
(A11055), goat anti-rabbit IgG (A11008) or donkey anti-mouse IgG (A11001), all from 
Life Technologies) in PBST for 45 minutes at room temperature. Cells were then washed 
three times with PBST and incubated with 4’-6’-diamino-2-phenylindole (DAPI) at a 
concentration of 0.001 mg/mL for 20 minutes at room temperature. Cells were then 
washed twice with PSBT and covered with PBS. Images were obtained with a Leica 
Microsystems DM1000 fluorescence microscope and Leica Microsystems DFC360FX 
camera. U-CH1 cells cultured under normoxia or hypoxia were stained in parallel, and 
images were captured with the same microscope settings (i.e. exposure, gain and 
intensity) to allow direct comparison, at 10X and 20X lens objective using glass bottom 
culture dishes (P35G014C, MatTek Corporation). IgG controls were run in parallel with 
experimental samples to detect non-specific binding. 
 
2.2.3 Real-time PCR 
 Cells were harvested directly in TRIzol® Reagent (Invitrogen, Life 
Technologies). Total RNA was extracted according to the manufacturer’s protocol and 
quantified using a NanoDrop 2000 spectrophotometer (Thermo Scientific). For each 
sample, 0.5 µg RNA was used for cDNA synthesis using iScript Reverse Transcriptase 
(Bio-Rad Laboratories). Real-time PCR was performed using the Bio-Rad CFX384 
system. PCR reactions were run in triplicate using 27 ng of cDNA per reaction and 25 
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µm forward and reverse primers (sequences provided in Table 1.1) with 2X SsoFast 
EvaGreen Supermix (Bio-Rad Laboratories). The PCR program was an initial 2 minutes 
at 95° C for denaturing; 10 seconds at 95° C for denaturing; 20 seconds 
annealing/elongation at 60° C for a total of 40 cycles. Gene expression was normalized 
relative to a standard curve (1/5 serial dilution with initial input of 0.1 µg/µL) made from 
a mixture containing human chordoma cells (U-CH1), human foreskin fibroblast cells 
and human embryonic stem cell (CA2) RNA in a 2:2:1 ratio. (n=3; N=3-4). 
 
2.2.4 Cell growth assay 
 U-CH1 cells were plated at a density of 3,430 cells/cm2 in chordoma media or 
with rCCN2domain4 media in 12-well plates (Nunc, Thermo Scientific) and maintained 
under either normoxic or hypoxic conditions. Cells were then trypsinized and counted 
with a hemocytomter using Trypan Blue to exclude non-viable cells (15250, Gibco) in 
triplicate on a phase contrast light microscope every 24 hours over 8 days (n=3; N=3). 
 
2.2.5 Cell migration assay 
 U-CH1 cells were plated in chordoma media at 25,714 cells/cm2 in 12-well plates 
(Nunc, Thermo Scientific) and maintained under either normoxic or hypoxic conditions. 
After 24 hours, media was changed to IMDM/RPMI (4:1) with 0.2% FBS to permit cell 
survival but minimize confounding effects of cell proliferation. After 24 hours, an 
artificial “scratch wound” was created using a 200 µl pipette tip. Cells were imaged at 0, 
12, 24, 36 and 48 hours at the exact location of the scratch. Every 24 hours, cells were   
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Table 1.1. Primer sequences used for real-time PCR gene expression analysis. 
 
Gene Name Primer Sequence (5’ to 3’) 
CCN1 Fwd- ACCGCTCTGAAGGGGATCT 
Rev- ACTGATGTTTACAGTTGGGCTG 
CCN2 Fwd- TCCCAAAATCTCCAAGCCTA 
Rev- GTAATGGCAGGCACAGGTCT 
CCN3 Fwd- AGTGATGGTCATTGGGACCTG 
Rev- CCTCTGGTAGTCTTCAGCTCC 
CCN5 Fwd- GCGACCAACTCCACGTCTG 
Rev- TCCCCTTCCCGATACAGGC 
T Fwd- TGAGACCCAGTTCATAGCGG 
Rev- TGCTGGTTCCAGGAAGAAGC 
CD24 Fwd- CTCCTACCCACGCAGATTTATTC 
Rev- AGAGTGAGACCACGAAGAGAC 
ACAN Fwd- TGAGGAGGGCTGGAACAAGTACC 
Rev- GGAGGTGCTAATTGCAGGGAACA 
FOXA1 Fwd- GCAATACTCGCCTTACGGCT 
Rev- TACACACCTTGGTAGTACGCC 
CA12 Fwd- TGGCATTCTTGGCATCTGTA 
Rev- TTGGTGGCTGGCTTGTAAAT 
SOX5 Fwd- CAGCCAGAGTTAGCACAATAGG 
Rev- CTGTTGTTCCCGTCGGAGTT 
SOX6 Fwd- TACCTCTACCTCACCACATAAGC 
Rev- ACATCGGCAAGACTCCCTTTG 
SOX9 Fwd- AGCGAACGCACATCAAGAC 
Rev- CTGTAGGCGATCTGTTGGGG 
HIF1A 
 
Fwd- ATCCATGTGACCATGAGGAAATG 
Rev- TCGGCTAGTTAGGGTACACTTC 
VEGFA 
 
Fwd- AGGGCAGAATCATCACGAAGT 
Rev- AGGGTCTCGATTGGATGGCA 
GLUT1 Fwd- GGCCAAGAGTGTGCTAAAGAA 
Rev- ACAGCGTTGATGCCAGACAG 
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briefly washed with PBS and media was replaced. Images were exported to ImageJ 
software and the polygon selection tool was used to calculate the area of new cell 
migration at each time point. The percentage of wound closure was calculated using the 
formula “[(Areat-0h – Areat-Δh)/Areat-0h] × 100%”, as previously reported  34 (n=4; N=4). 
 
2.2.6 Sphere formation assay 
 U-CH1 cells were plated using standard protocols for sphere formation 35, at 
1,500 cells per well in 24-well non-adherent plates (Nunc, Thermo Scientific) and grown 
for 10 days in serum-free DMEM/F12 (Invitrogen, Life Technologies) supplemented 
with B27 (1:50 dilution), bFGF (20 ng/mL), EGF (20 ng/mL) and 1% methylcellulose 
(R&D Systems). For rCCN2domain4 experiments, the above media was supplemented with 
100 ng/mL rCCN2. Cells were fed every other day with the media added cumulatively 
(i.e. not aspirated) at each feeding and spheres (defined as ≥ 50 µM) were counted after 
10 days. The efficiency of sphere formation (number of spheres per 1000 cells) was 
calculated, as previously described 35 (N=3-4). 
 
2.2.7 Flow cytometry 
 U-CH1 cells were harvested from monolayer by enzymatic dissociation in 0.25% 
Trypsin and resuspended in 10% FBS in PBS. Cells were counted and resuspended at a 
concentration of 1×106 cells/mL in Aldefluor buffer (Stemcell Technologies).  2 µl/mL 
Aldefluor reagent (Stemcell Technologies) was added to determine aldehyde 
dehydrogenase (ALDH) activity, with a separate ALDH inhibitor 
(diethylaminobenzaldehyde (DEAB)) to act as a negative control (Stemcell 
51 
 
Technologies). Samples were incubated for 30 minutes and then centrifuged at 470g for 7 
minutes. Media was then aspirated and cells were resuspended in Aldefluor buffer (1×106 
cells in 200 µl) with fluorochrome-conjugated antibodies specific to human CD90 (Thy-1 
membrane glycoprotein) (555596, BD Biosciences), CD105 (endoglin) (562380, BD 
Biosciences) and CD133 (prominin) (130090826, Miltenyi Biotec) and appropriate IgG 
controls for 30 minutes. After incubation, 500 µl of Aldefluor buffer was added to each 
tube and then cells were centrifuged at 470 g for 7 minutes. Media was then aspirated to 
the seam line of tubes and ALDH and cell surface expression was acquired using a LSR 
II flow cytometer (BD Biosciences) at the London Regional Flow Cytometry Facility, 
and analyzed on FlowJo software program. U-CH1 cells were also characterized based on 
side scatter using cluster gating with FlowJo software, as previously described 36. Both 
ALDH and antibodies were titrated beforehand to determine the appropriate 
concentration for experiments. The amount of ALDH and cell surface receptors in 
experimental samples were then determined using their respective isotype (IgG) controls. 
The effects of rCCN2domain4 were assessed following 6 days of treatment. For these 
experiments, cells were maintained in chordoma media supplemented with 5% or 10% 
FBS and 100 ng/mL rCCN2domain4.  
 
2.2.8 Statistical analysis 
 All data was collected and statistical analysis was performed using GraphPad 
Prism 6.0 Software. An unpaired Student’s t test (between 2 groups); 1-way ANOVA 
(between ≥3 groups; comparing one condition) or 2-way ANOVA (between ≥3 groups; 
comparing two conditions) with either a Tukey’s multiple comparisons test or Dunnett’s 
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test to examine differences compared to a control group were performed on respective 
experiments. 
 
2.3 Results 
2.3.1. Expression of T and matricellular proteins in U-CH1 cells 
 The expression of the known chordoma marker T and the matricellular proteins 
CCN1 and CCN2 were first assessed in U-CH1 cells grown using established protocols 
37. Immunocytochemistry demonstrated nuclear localization of T in a subset of U-CH1 
cells (both vacuolated and non-vacuolated cell morphologies) (Figure 2.1A), which is in 
keeping with previous reports 38. It is important to note that vacuolated cells were defined 
as cells that had more than 2 vacuoles. There were no significant changes in the number 
of nuclei of cells positive for T under normoxia (20.4 ± 2.1%) compared to hypoxia (22.6 
± 2%). We also found expression of CCN1 and CCN2 (in both vacuolated and non-
vacuolated cell morphologies), localized to perinuclear and cytoplasmic region of cells 
(Figure 2.1B). The corresponding IgG controls for cell staining indicated no detection 
non-specific staining (Figure 2.2). 
 
2.3.2. Effects of hypoxia on U-CH1 gene expression 
 To determine the effects of changes in oxygen levels in the cell microenvironment 
on the chordoma gene expression profile, U-CH1 cells were grown in either normoxic 
(20% O2) or hypoxic (2% O2) conditions and a panel of genes were investigated. We first 
assessed expression of CCN family members, specifically CCN1 39-40, CCN2 41-42, CCN3 
43-44 and CCN5 45-46 which have been implicated in modulating cell proliferation, cell  
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Figure 2.1. Localization of T, CCN1 and CCN2 in U-CH1 cells maintained using 
established culture protocols. Representative images demonstrate nuclear localization 
of T and perinuclear and diffuse cytoplasmic localization of CCN1 and CCN2 in U-CH1 
cells. Interestingly, protein expression is detected throughout the heterogenous cell 
population in both vacuolated (arrow) and non-vacuolated (arrowhead) cells. (n=3; N=3; 
scale bar= 250 µm) 
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Figure 2.2. IgG controls for immunocytochemistry of T, CCN1, and CCN2 in UCH-
1 cells. (n=3; N=3; scale bar = 500 µm) 
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adhesion, angiogenesis, cell migration, metastasis and epithelial-mesenchymal transition 
in a variety of cancers. Our results indicate that culture of U-CH1 cells in hypoxia 
promotes increased expression of CCN3 and CCN5 compared to normoxia, while no 
change in CCN1 or CCN2 expression was detected (Figure 2.3A). We next investigated 
the expression of SOX family members SOX5, SOX6 and SOX9. Our results demonstrate 
that hypoxia induces a significant increase in SOX6 and and SOX9 but not SOX6 
expression in U-CH1 cells compared to cells in normoxia (Figure 2.3B). In order to 
determine if the gene expression of early notochord progenitor markers was changed in 
U-CH1 cells under hypoxic conditions, we examined the expression of T, CD24, FOXA1, 
ACAN and CA12 (Figure 2.3C). Under hypoxia, we found that there was significant up-
regulation in the expression of all these markers, with T and CA12 having the most 
significant increase (P< 0.001) followed by CD24 and ACAN (P<0.01) and then FOXA1 
(P<0.05). Together, these data suggest that hypoxia may be promoting a progenitor-like 
phenotype in U-CH1 cells. Lastly, to determine if HIF1-α was preferentially activated 
under hypoxic conditions, we interrogated the expression of HIF1α and its downstream 
targets VEGF-A and GLUT1 (Figure 2.3D). Although no change was detected in the 
expression of HIF1α,  chordoma cells in hypoxia demonstrated a significant increase in 
the expression of both VEGF-A and GLUT1 compared to cells in normoxia. 
 
2.3.3. Changes in CCN1 localization under hypoxia 
 Protein localization in U-CH1 cells maintained in either hypoxic or normoxic 
conditions was directly compared (Figure 2.4 and 2.5). Under hypoxia, CCN1 
demonstrated cytoplasmic and cell surface localization compared to cells maintained in  
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Figure 2.3. Effect of hypoxia on gene expression of U-CH1 cells. Gene expression was 
assessed in U-CH1 cells maintained in either normoxic (20% O2) or hypoxic (2% O2) 
conditions by real-time PCR. Expression of (A) members of the CCN family (CCN1, 
CCN2, CCN3, CCN5), (B) members of the SOX transcription factor family (SOX5, 
SOX6, SOX9), (C) notochord markers (CD24, T, AGG, FOXA1, CA12) and (D) hypoxia 
inducible factor (HIF1A) and its downstream targets (VEGF-A, GLUT1) were 
investigated. (Unpaired Student’s t test; n=3; N=3-4; *= P ≤ 0.05, **= P ≤ 0.01, ***=P ≤ 
0.001, ****=P ≤ 0.0001) 
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Figure 2.4. Expression and localization of CCN1 and CCN2 in U-CH1 cells 
maintained under normoxic (20% O2) or hypoxic (2% O2) conditions. CCN1 is 
localized to the perinuclear and cytoplasmic region under normoxia and cytoplasmic and 
cell surface region of cells under hypoxia. CCN2 is localized to the nuclear and 
cytoplasmic region under normoxia and hypoxia. (n=3; N=3; scale bar = 250 µm) 
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Figure 2.5. Expression and localization of HIF1-α and T in U-CH1 cells maintained 
under normoxic (20% O2) or hypoxic (2% O2) conditions. HIF1-α is primarily 
localized to nucleus under normoxia and hypoxia. T is localized to the nuclear region 
under both normoxia and hypoxia (n=3; N=3; scale bar = 250 µm) 
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normoxia, where CCN1 was localized primarily to the perinuclear region and cytoplasm. 
HIF1-α was detected primarily in the nucleus of U-CH1 cells under both normoxia and 
hypoxia. In addition, there were no changes detected in either CCN2 or T localization in 
U-CH1 cells under normoxia or hypoxia. 
 
2.3.4. Hypoxia promotes U-CH1 cell growth and sphere formation but reduced cell 
migration 
 In order to investigate cell growth, U-CH1 cell numbers were counted every 24 
hours over 8 days under either normoxic or hypoxic conditions (Figure 2.6A). U-CH1 
cells demonstrated increased growth in hypoxia compared to normoxia at days 6, 7 and 8. 
In addition to changes at specific time points, there was also a significant increase in the 
rate of cell growth under hypoxia compared to normoxia when a linear regression was 
performed on cell counts plotted on a logarithmic scale. Interestingly, we found that there 
was no increase in cell growth at days 5 and 6 under normoxia. This was an unusual 
finding of our study and we suggest that future studies measure apoptosis throughout the 
assay to determine if it could have contributed to this finding.  
 
To investigate stem-like properties, sphere formation assays were conducted using U-
CH1 cells maintained under normoxic or hypoxic conditions (Figure 2.6B). 
Quantification of sphere formation following 10 days of culture demonstrated a 
significant 10-fold increase in sphere formation in U-CH1 cells maintained under 
hypoxia compared to normoxia. 
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Figure 2.6. Cell growth, migration and sphere formation of U-CH1 cells in normoxic 
(20% O2) or hypoxic (2% O2) conditions. (A) U-CH1 cells were counted every 24 
hours over 8 days and demonstrate increased growth in hypoxia versus normoxia at days 
6-8 (n=3; N=3). (B) U-CH1 cells were grown in suspension and spheres were counted 
after 10 days. Cells maintained under hypoxic conditions demonstrate a significant 
increase in sphere formation compared to normoxic conditions (N=3). (C) U-CH1 cells 
were plated and an artificial “scratch wound” was created. Cells were imaged at 12, 24, 
36 and 48 hours and the area of new cell migration borders was determined. Maintenance 
of cells in hypoxia significantly decreased cell migration at 12, 24 and 36 hours 
compared to cells in normoxia at the same time-point (n=4; N=4). (2-way ANOVA with 
Tukey’s test (A and C); Unpaired Student’s t test (B); *= P ≤ 0.05; **= P ≤ 0.001; ***= P 
≤ 0.0001; scale bar= 250 µm) 
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 To evaluate changes in U-CH1 cell migration in normoxia compared to hypoxia, a 
“scratch wound” assay was conducted to quantify cell migration over 48 hours (Figure 
2.6C). U-CH1 cells maintained under hypoxia demonstrate a significant decrease in 
migration at 12, 24 and 36 hours compared to cells maintained under normoxia at the 
same time-points. This difference was no longer apparent at 48 hours, as the majority of 
the wound appeared to be closed under both conditions. Taken together, these findings 
suggest that hypoxia could be promoting progenitor-like properties in U-CH1 cells.  
 
2.3.5. 11.2 kDa rCCN2 fragment promotes ACAN and COL2A1 gene expression in 
U-CH1 cells 
  Previous studies have demonstrated up-regulation of ACAN and COL2A1 gene 
expression in nucleus pulposus cells following stimulation with CCN2 47–49. In order to 
ensure bioactivity of rCCN2domain4 peptide in U-CH1 cells, we quantified expression of 
ACAN and COL2A1 in U-CH1 cells following 24 hour treatment with 50, 100 or 200 
ng/mL rCCN2domain4. Treatment of cells with 100 ng/mL rCCN2domain4 resulted in a 
significant increase in ACAN and COL2A1 under normoxia and hypoxia and treatment 
with 200 ng/mL rCCN2domain4 significantly increased COL2A1 under normoxia (Figure 
2.7). We therefore used a concentration of 100 ng/mL of rCCN2domain4 for all remaining 
assays. 
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Figure 2.7. Effect of recombinant rCCN2 on ACAN and COL2A1 gene expression in 
U-CH1 cells maintained under normoxic (20% O2) or hypoxic (2% O2) conditions. 
U-CH1 cells were treated with 50, 100 or 200 ng/mL of rCCN2 for 24 hours and 
harvested for gene expression analysis. Treatment of cells with 100 ng/mL of 
rCCN2domain4 promoted a significant increase in ACAN and COL2A1 gene expression in 
cells maintained in normoxia and hypoxia; treatment with 200 ng/mL of rCCN2domain4 
significantly increased COL2A1 gene expression under normoxia. (1-way ANOVA with 
Dunnet’s test; n=3; N=3; *= P ≤ 0.05; **= P ≤ 0.001) 
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2.3.6. Effects of rCCN2domain4 on U-CH1 gene expression under normoxia and 
hypoxia 
To determine the effects of rCCN2domain4 on the chordoma gene expression profile, U-
CH1 cells were grown with rCCN2domain4 under either normoxic or hypoxic conditions for 
24 hours, and a panel of genes was investigated. We first assessed expression of CCN1, 
CCN2, CCN3 and CCN5 and found a significant increase in all of these genes with the 
addition of rCCN2domain4 under either normoxia or hypoxia (Figure 2.8A). Interestingly, 
we noted differences in in the expression levels of CCN family members between vehicle 
controls and the baseline gene expression presented in  Figure 2.2. This may be due to 
differences in the media used for cell culture, since FBS was reduced from 10% to 5% in 
rCCN2 treatment conditions.  
 
 We also assessed the expression of SOX family members and found a significant 
increase in SOX5 and SOX6 gene expression with the addition of rCCN2domain4 under 
normoxia (Figure 2.8B). Lastly, we investigated the expression of early notochord 
markers (T, CD24, FOXA1, ACAN and CA12) (Figure 2.8C). U-CH1 cells treated with 
rCCN2domain4 in normoxia demonstrated a significant increase in the expression of early 
notochord development markers (T, CD24, FOXA1 and ACAN) compared to untreated 
controls. In hypoxia, treatment of U-CH1 cells with rCCN2domain4 induced a significant 
increase in the expression of T, CD24 and ACAN. Interestingly, the combined effect of 
rCCN2domain4 and hypoxia produced an additive response in a subset of gene expression, 
specifically for T, CD24 and ACAN. Together, these data suggest that rCCN2domain4 may  
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Figure 2.8. Effect of rCCN2domain4 on U-CH1 gene expression in normoxic (20% O2) 
and hypoxic (2% O2) culture environments. Expression of (A) members of the CCN 
family (CCN1, CCN2, CCN3, CCN5), (B) members of the SOX transcription factor 
family (SOX5, SOX6, SOX9) and (C) notochord markers (T, CD24, FOXA1, ACAN, 
CA12) were investigated in U-CH1 cells treated with 100 ng/mL of rCCN2 for 24 hours 
in either normoxic or hypoxic conditions. (Unpaired Student’s t test; n=3, N=3; *= P ≤ 
0.05, **= P ≤ 0.01, ***=P ≤ 0.001, ****=P ≤ 0.0001) 
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be promoting a progenitor-like phenotype in U-CH1 cells, with the effects being more 
robust under normoxia than hypoxia. 
 
2.3.7. In normoxia rCCN2domain4 significantly increases U-CH1 sphere formation but 
does not increase cell growth  
 Sphere formation was determined for U-CH1 cells grown in either normoxia or 
hypoxia with the addition of rCCN2domain4 for 10 days. We found a significant 1.7-fold 
increase in sphere formation with the addition of rCCN2domain4 compared to vehicle 
control in normoxia.  In contrast, no changes in the efficiency of sphere formation were 
observed in the presence of rCCN2domain4 in hypoxia (Figure 2.9A). We then assessed U-
CH1 cell growth in the presence of rCCN2domain4 in normoxia, as these culture conditions 
increased more progenitor markers and sphere formation in U- CH1 cells. Over 8 days, 
treatment of U-CH1 cells with rCCN2domain4 did not alter cell growth (Figure 2.9B). We 
also performed a linear regression analysis of the data plotted on a logarithmic scale and 
found no changes in the rate of cell growth between U-CH1 cells treated with 
rCCN2domain4 and vehicle control.  
 
2.3.8. Maintenance of U-CH1 cells in hypoxia leads to a decrease in the number of 
vacuolated cells 
 To determine if culture of U-CH1 cells in hypoxia or the treatment of cells with 
rCCN2domain4 affected the morphological characteristics of the heterogeneous chordoma 
cell population, we assessed intracellular complexity (side scatter) of cells by flow 
cytometry. Recent studies have suggested that non-vacuolated chordoma cells (with low  
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Figure 2.9. Sphere formation and cell growth in U-CH1 cells treated with 
rCCN2domain4. (A) Sphere formation was assessed in U-CH1 cells treated with 
rCCN2domain4 (100 ng/mL) in either normoxic or hypoxic conditions. The efficiency of 
sphere formation was assessed at day 10 as the number of spheres per 1000 cells. Data is 
presented as fold change from vehicle control (set to 1; indicated by dashed line) for cells 
maintained in either normoxic or hypoxic culture conditions. Treatment of cells with 
rCCN2domain4 induced a significant increase in sphere formation compared to vehicle 
control when cells were maintained in normoxia (N=3-4). (B) U-CH1 cells were 
maintained in normoxic conditions and treated with 100 ng/mL of rCCN2domain4 or 
vehicle control and cell number was quantified every 24 hours over 8 days. No change in 
cell growth was detected following treatment with rCCN2domain4 compared to vehicle 
control (n=3, N=3). (Unpaired Student’s t test (A); 2-way ANOVA with Tukey’s test (B); 
*= P ≤ 0.05; scale bar= 250 µm) 
 
 
 
 
 
 
 
 
 
 
67 
 
side scatter profiles) act as progenitor cells that give rise to the larger vacuolated cells 
(with high side scatter profiles) 50. We first assessed cell populations maintained in either 
normoxia or hypoxia and found a significant decrease (P= 0.03) in the percentage of 
vacuolated cells in hypoxia compared to cells maintained in normoxia (3.8 ± 0.6% vs. 6.0 
± 0.3%, respectively). Interestingly, the addition of rCCN2domain4 did not significantly 
alter the percentage of U-CH1 cells demonstrating a vacuolated morphology when cells 
were treated in either normoxia (5.7 ± 0.9 % control vs. 5.8 ± 1.1% rCCN2) or hypoxia 
(3.7 ± 0.6% control vs. 3.9 ± 0.4% rCCN2) (Figure 2.10A). 
 
2.3.9. Expression of mesenchymal stromal cell differentiation markers CD90 and 
CD105 in U-CH1 cells  
 We next investigated expression of cell surface markers CD90 and CD105, as 
they have been found highly expressed in U-CH1 cells 57 and act as differentiation 
markers in mesenchymal stromal cells 58-59. No significant changes in the percentage of 
CD90+ or CD105+ U-CH1 cells were detected in normoxic or hypoxic culture conditions 
or with the addition of rCCN2domain4. We found there was a trend towards a decrease in 
CD90+ U-CH1 cells under normoxia compared to hypoxia (20.1 ± 5.7% in normoxia vs. 
37 ± 2.5% in hypoxia). In contrast, there was a trend towards an increase in CD105+ 
UCH-1 cells under normoxia compared to hypoxia (18.7 ± 10.5% in normoxia vs. 6.7 ± 
1.8% in hypoxia). (Figure 2.10A and B).	   	  
	  
 To investigate if a cancer stem cell population could be detected in U-CH1 cells, 
the expression of CD133 and the activity of aldehyde dehydrogenase (ALDH) were  
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Figure 2.10. Side scatter distributions and expression of cell surface markers CD90 
and CD105 in U-CH1 cells maintained in normoxic or hypoxic conditions with or 
without rCCN2domain4 in normoxic (20% O2) or hypoxic (2% O2) conditions. (A) 
Cluster gating was used to determine the intracellular complexity of U-CH1 cells. There 
was a significant increase in the number of vacuolated cells (side scatter high) under 
normoxia compared to hypoxia with minimal changes with the addition of rCCN2domain4. 
When placed under normoxia, U-CH1 cells showed a trend towards decreased expression 
of (A) CD90 and increased expression of (B) CD105 (N=3). 
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Figure 2.11. Expression of cell surface marker CD133 and ALDHhi activity using 
rCCN2domain4 in normoxic (20% O2) or hypoxic (2% O2) conditions. Expression of 
(A) CD133 and (B) ALDHhi activity. There was minimal expression of (A) CD133 
(N=3) and (B) ALDHhi activity under all treatment conditions (N=2). 
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determined as they are common markers of cancer stem cells 51–56. We detected 
minimal expression of CD133 (>0.01% positive cells) in U-CH1 cells in all culture 
conditions (Figure 2.11A). Similarly, we detected minimal ALDH activity (>0.02% 
ALDHhi cells) in U-CH1 cells in all culture conditions (Figure 2.11B). 
 
2.4 Discussion 
 The tumor microenvironment is a complex environment composed of a variety of 
different cell types such as cancer cells, stromal fibroblasts, endothelial cells, as well as 
secreted proteins, oxygen levels and components of the extracellular matrix, including 
matricellular CCN proteins 60. The current study investigated the effects of hypoxia and 
the specific matricellular protein CCN2 on U-CH1 cells, as there is strong indication that 
these factors could be involved in the regulation of chordoma cell biology 4-5. In our 
study, we found that hypoxia had the greatest ability to promote progenitor-like 
properties in U-CH1 cells compared to the addition of rCCN2domain4. We also found the 
expression of CCN family members in U-CH1 cells and demonstrated their expression to 
be regulated by the chordoma microenvironment. In addition, we demonstrated that the 
effects of rCCN2domain4 and hypoxia were additive for the expression of a specific subset 
of notochord progenitor markers. 
 
 In this study, we demonstrate the expression of CCN matricellular proteins in U-
CH1 cells through immunolocalization and gene expression analysis. To our knowledge, 
this is the first investigation of CCN1, CCN3 and CCN5 expression in chordoma and 
suggests they could have a potential role in chordoma cell biology. Through gene 
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expression analysis, we found increased expression of CCN3 and CCN5 under hypoxia. 
These findings are in keeping with previous studies that found increased expression of 
matricellular proteins under hypoxia compared to normoxia. Specifically, CCN1 and 
CCN3 were increased human choriocarcinoma cells 61, CCN1 was also increased in 
retinal vascular endothelial cells 62, and CCN2 was increased in primary tubular epithelial 
cells 63 under hypoxia compared to normoxia. In addition, we also found localization of 
CCN1 in the perinuclear and cytoplasmic region of cells, as well as localization of CCN2 
in the nucleus and cytoplasmic region under normoxia and hypoxia. Previous studies 
have shown the localization of CCN1 in nuclei of prostate carcinoma 64, stretched bladder 
smooth muscle cells 65 and breast cancer cells 66 and CCN2 in melanoma cells 67. The 
exact role of CCN proteins within the nucleus remains unknown, and is a future area of 
study. 
 
When U-CH1 cells were maintained in hypoxia, we found an increase in the 
expression of early notochord markers (T, CD24, FOXA1, ACAN and CA12), sphere 
formation and cell growth. There are currently opposing reports as to the effects of 
hypoxia on human chordoma cell growth 37, 68; our finding are  consistent with those of  
Ostroumov et al., which reported an increase in cell growth in a primary human 
chordoma cell line over 5 days under hypoxia compared to normoxia. Further validating a 
change in U-CH1 cell phenotype in hypoxia, we demonstrated a decrease in the number 
of vacuolated U-CH1 cells under hypoxia compared to normoxia, which is in keeping 
with a recent study suggesting that vacuolated cells represent a more differentiated cell 
type within the heterogeneous U-CH1 cell population 50. Our findings are well aligned 
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with studies in other cancers such as in glioma and glioblastoma 22 and ovarian cancer 23, 
which reported the promotion of stem and progenitor cell properties following culture of 
cells in hypoxia. Interrogating the expression of CD90 and CD105 demonstrated that 
these cell surface markers are expressed in U-CH1 cells, and further studies are warranted 
to determine if they could be used as markers of chordoma cell differentiation.  
 
 In hypoxic conditions, cells often demonstrate increased activity of HIF1-α, a 
transcription factor that binds to hypoxia-response elements to activate the expression of 
genes involved in a variety of cellular processes including proliferation, angiogenesis, 
metabolism, apoptosis and the maintenance of an undifferentiated state in cancer cells 69–
73. For example, vascular endothelial growth factor (VEGF) and glucose transporter 1 
(GLUT1) are direct downstream targets of HIF1-α involved in angiogenesis and 
glycolysis, respectively 74. Under normoxic conditions, the α subunit of the HIF1-α 
protein is rapidly degraded through hydroxylation of two key proline residues in the 
oxygen-dependent degradation domain 75. However, under hypoxic conditions, HIF1-α 
becomes stabilized and binds to the aryl hydrocarbon receptor nuclear translocator in the 
nucleus. In our study, we did not detect the induction of HIF1α gene expression in U-
CH1 cells maintained in hypoxia, however; we detected a significant up-regulation of 
VEGF-A and GLUT1 gene expression, suggesting increased HIF1-α activity. Studies 
using ovarian 23 and glioma 73 cancer cells have shown increased HIF1-α expression 
under hypoxia and future studies should quantify nuclear and cytoplasmic fractions of 
HIF1-α to  directly asssess HIF1-α activity in U-CH1 cells.  
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Compared to the effects of hypoxia on U-CH1 cells, we found that treatment of 
cells with exogenous CCN2 induced the expression of fewer notochord markers (T, 
CD24, FOXA1 and ACAN) and SOX family members (SOX5 and SOX6). To accompany 
these changes in gene expression, we found an increase in sphere formation but no 
changes in cell growth. Interestingly, we found that addition of rCCN2domain4 to cells 
grown in hypoxia induced even fewer changes in the expression of notochord progenitor 
markers, no change in the expression of SOX family members, and did not promote 
sphere formation.  These differences in the effect of exogenous CCN2 treatment in 
normoxic or hypoxic conditions may be related to the cell-type specific effects of CCN 
proteins. We demonstrated that U-CH1 cells are more progenitor-like under hypoxia than 
in normoxia, suggesting that in these conditions, cells may be expressing different 
integrins, cell surface receptors or CCN binding proteins that mediate CCN2-dependent 
signalling. Furthermore, recent studies have established an intriguing direct feedback 
between HIF1-α and CCN2 in related cell types.  In chondrocytes, HIF1-α has been 
shown to directly interact with the CCN2 promoter and the addition of rCCN2 was shown 
to increase HIF1-α mRNA and protein levels 75. In nucleus pulposus cells, the loss of 
HIF1-α was reported to increase CCN2 expression 76. Based on these findings, we 
speculate there could be interaction between HIF1-α and CCN2 in chordoma cells, such 
that rCCN2domain4 is decreasing HIF1-α activity under hypoxia but promoting HIF1-α 
activity under normoxia. In addition, there could also be separate pathways downstream 
of CCN2 interactions with U-CH1 cells that are HIF1-α independent, such as AP1 or 
Smad signalling 77 that could be involved in regulating progenitor-like properties. Future 
studies could interrogate the mechanisms responsible for the differential effects of 
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rCCN2 observed in  normoxia and hypoxia, using specific pharmacological manipulation 
of candidate signalling pathways. 
  
  Despite the interesting outcomes of these studies, we acknowledge some inherent 
limitations. The first is the use of in vitro assays, which are not entirely reflective of the 
tumor microenvironment in its entirety or the heterogeneous clinical presentation of 
chordomas. Future experiments should therefore incorporate xenotransplantation 
experiments to assess the effects of CCN2 in vivo. To investigate the effects of 
exogenous CCN2, we also used a peptide fragment corresponding to the fourth domain of 
CCN2 as opposed to the full-length peptide. Although this CCN2 peptide fragment has 
been shown to modulate cell adhesion, migration, angiogenesis and differentiation in 
other cell types 41,76,79–79 and can be found in the tissue microenvironment following 
endogenous CCN2 cleavage 80–83 it may not effectively recapitulate all functions of the 
full-length CCN2 protein. Lastly, we did not perform gain or loss of functions 
experiments using CCN2 in U-CH1 cells, and this is a future area of study. 
 
 Taken together, findings from this study highlight the importance of the tumor 
microenvironment in the regulation of human chordoma cell phenotype. We demonstrate 
that components of the microenvironment (i.e. hypoxia and CCN2) influence the 
chordoma cell phenotype and that cells respond to hypoxia and CCN2 by up-regulating 
progenitor-like properties. Since there is mutual interaction between the 
microenvironment and tumor cells, we suggest that future studies focus on examining 
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more components of the microenvironment, as this would provide further insight into 
chordoma pathogenesis. 
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3.1 Summary and conclusions 
 In this study, we sought to investigate microenvironmental regulation of U-CH1 
cell properties by specifically investigating the effects of hypoxia and CCN2, as studies 
have suggested that these may serve as important regulators of chordoma pathogenesis 1-
2. We hypothesized that hypoxic conditions and/or increased levels of CCN2 would alter 
the phenotype and functional properties of human chordoma cells, promoting progenitor-
like characteristics specific to the notochordal tissue of origin. 
 
We explored our hypothesis with two specific objectives: 
1) To examine the effect of hypoxia on human U-CH1 chordoma cells. 
2) To examine the effect of CCN2 stimulation and the additive effects of CCN2 and 
hypoxia on human U-CH1 chordoma cells. 
 
 These studies enabled us to conclude that hypoxia and CCN2 both promoted 
progenitor-like properties in U-CH1 cells, including increased progenitor cell self-
renewal and the expression of genes associated with the notochord tissue of origin. 
Interestingly, hypoxia had the greatest ability to induce progenitor-like properties and the 
effects of CCN2 were more pronounced when cells were treated in normoxia than in 
hypoxia (Figure 3.1).  
 
3.2 Significance of research 
 Hypoxia and CCN2 have been shown to regulate stem and progenitor cell 
differentiation and cancer cell biology; however, there are limited studies examining the 
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Figure 3.1 Working model illustrating the effects of hypoxia and CCN2 on U-CH1 
cells. Results from the current study demonstrate an increase in the expression of 
notochord progenitor markers, cell growth and self-renewal in chordoma cells in hypoxia 
compared to normoxia. In normoxia, exogenous CCN2 (indicated as black circles) 
increased the expression of progenitor markers and sphere formation; however these 
effects were not as pronounced as hypoxia alone. Lastly, the addition of CCN2 in 
hypoxia induced the expression of only a subset of progenitor markers. The large green 
triangles represent chordoma cells in either microenvironment, with potential 
mechanisms underlying the change in cell phenotype illustrated. In hypoxia, we 
demonstrated increased HIF1-α activity, which may be decreased by the addition of 
CCN2. In contrast, in normoxia, where endogenous HIF1-α activity is lower, the addition 
of CCN2 may alter the U-CH1 phenotype by increasing HIF1-α activity. Modulation of 
HIF1-α activity may contribute to the differences in progenitor-like properties reported in 
U-CH1 cells. Given the change detected in the chordoma cell phenotype, it may be that 
CCN2 is interacting with different integrin or cell surface receptors or downstream 
pathways independent of HIF1-α (such as AP-1 or SMAD) on U-CH1 cells under 
hypoxia compared to normoxia, resulting in differential downstream effects. 
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effects of hypoxia on human chordoma cells and no studies examining the effects of 
CCN2 on human chordoma cells. There are two studies that examined the effects of 
hypoxia on cell growth in chordoma cells. The first study used primary human chordoma 
cells maintained under normoxia (20% O2) or hypoxia (5% O2) under low (1 g/L) or high 
(4.5 g/L) glucose concentrations over 5 days 3. The authors report an increase in cell 
proliferation under hypoxia compared to normoxia over 5 days, which was independent 
of the glucose concentration in the culture media. The second study used U-CH1, CH 8 
and GB 60 human chordoma cells maintained under normoxia (20% O2) or hypoxia (5% 
O2) for 7 days with or without glucose (ranging from 2-6 g/L) and measured cell growth 
after 7 days 4. The study reported no difference in cell proliferation under hypoxia 
compared to normoxia for all 3 cell lines, and similarly reported no effects of glucose. 
The increase we demonstrate in U-CH1 cell growth under hypoxia may be attribute to the 
lower oxygen level (2% O2) used in the current study. In addition, we maintained our 
cells in hypoxia for at least 1-2 passages before performing our cell growth assay, 
whereas the study using U-CH1 cells did not, which could also explain differences in the 
findings. Furthermore, the study using primary chordoma cells also found that the 
optimal pH for chordoma cells was alkaline as this increased cell proliferation and 
intracellular tyrosine phosphorylation without inducing apoptosis 3.  
 
 Our study highlights the importance of the tumor microenvironment, as we 
demonstrated that hypoxia and CCN2 have important roles in the maintenance of a 
progenitor-like population in U-CH1 cells. We demonstrated that hypoxia has the greatest 
ability to promote progenitor-like properties in U-CH1 cells and that the effects of CCN2 
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were more pronounced under normoxia than under hypoxia. Hypoxia increased the 
expression of the majority of the notochord markers and increased both cell proliferation 
and sphere formation compared to rCCN2. We also found additive effects of rCCN2 and 
hypoxia on the gene expression of a subset of notochord progenitor markers. It is 
important to note that the increase in progenitor-cell characteristics could be interpreted 
as either increased expression of these markers in all cells or an increase in the number of 
progenitor cells in the heterogeneous population. Our data suggests there may be an 
increase in the number of progenitor cells within the heterogeneous cell population. 
While we did not directly assess the percentage of U-CH1 cells expressing progenitor 
markers in the current study, the increases observed in the efficiency of sphere formation 
in hypoxia suggest an increase in the number of progenitor cells within the heterogeneous 
population under these conditions. 
 
The differences observed in the effect of exogenous CCN2 treatment of U-CH1 
cells in normoxic or hypoxic conditions may be related to the cell-type specific effects of 
CCN proteins. Since we demonstrated that U-CH1 cells are more progenitor-like in 
hypoxia than in normoxia, cells may consequently be expressing different integrins, cell 
surface receptors or CCN2 binding proteins that mediate CCN2-dependent signalling. 
Furthermore, previous studies have showed that HIF1-α and CCN2 each regulate the 
expression of the other 5–7. As such there could be differences in the interaction between 
HIF1-α and CCN2 in U-CH1 cells, such that rCCN2domain4 is decreasing HIF1-α activity 
under hypoxia but promoting HIF1-α activity under normoxia.  In addition, there could 
also be separate pathways downstream of CCN2 that are HIF1-α independent, such as 
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AP1 or Smad signalling that could be involved in regulating the response of UCH-1 cells 
to CCN2 and the induction of progenitor-like properties 8.  
 
 Given the change in cell phenotype observed, future experiments could focus on 
examining differences in the expression of CCN2-binding integrin receptors (such as 
αvβ1 and αvβ3 9-10) in U-CH1 cells maintained in normoxia or hypoxia using 
immunolocalization and real-time PCR gene expression analysis. Differences in the 
expression of additional cell surface receptors could likewise be examined in U-CH1 
cells maintained under normoxia or hypoxia could be assessed using flow cytometry. To 
detect differences in expression of extracellular CCN2 binding proteins (ex. fibronectin, 
vitronectin or decorin 11) by U-CH1 cells in normoxia versus hypoxia, western blot 
analysis could be conducted on the media or extracellular matrix fraction of confluent U-
CH1 cell cultures. HIF1-α levels could be quantified in U-CH1 cells under normoxia or 
hypoxia, with or without rCCN2domain4 by western blot analysis of both the nuclear and 
cytoplasmic proteins to quantify changes in expression level, or subcellular localization. 
Lastly, western blot analysis could be used to determine changes in the activation of 
Smad or AP-1 signaling pathways under normoxia and hypoxia, and with the addition of 
rCCN2domain4.  
 
 Currently, there are very few treatment options available for patients with 
chordoma. Most patients undergo resection of the tumor, but this is often associated with 
a high rate of recurrence and decreased survival 3-4. In addition, the use of radiation 
therapy has mixed results on patients with chordoma 5-6 complicated by the proximity of 
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the tumor to the spinal cord, which makes it difficult to administer high doses of 
radiation. There are no drugs approved by the FDA for the majority of patients of 
chordomas with a major issue being that chordomas are slow growing tumors and most 
chemotherapy drugs target rapidly proliferating cells. Since our study demonstrates U-
CH1 progenitor properties are significantly increased under hypoxia, with increased cell 
proliferation and self-renewal, it could be worthwhile to explore hypoxia signaling 
pathways as potential therapeutic targets. Studies have shown that regions of hypoxia 
have increased resistance to drug therapy and that HIF1-α can act on a variety of different 
pathways to increase drug efflux pumps such as MDR1 16 and inhibit anti-apoptotic genes 
such as BCL2 17. Further studies could explore if patients with chordomas would benefit 
from HIF-targeting drugs in combination with surgery for a more efficient treatment 
option. A variety of drugs, including PX-12 and YC-1 have shown to decrease HIF1-α 
levels in in vivo mouse xenograft models using breast cancer and human colon carcinoma 
18, and hepatoma, stomach carcinoma, renal carincoma, cervical carcinoma and 
neuroblastoma cells cancer  and breast cancer cells 19. In these studies, the tumors showed 
decreased tumor growth 18-19 and angiogenesis 19. Future studies should use in vivo mouse 
xenograft models with U-CH1 cells with HIF1-α targeting drugs to determine if they 
reduce cell growth or self-renewal properties in tumors. 
 
3.3 Limitation of the research and suggestions for future studies  
 In addition to the suggestions for future studies mentioned above, one major 
limitation of our research is the use of the rCCN2 peptide. This 253-349 amino acid 
peptide corresponds to the fourth domain of the CCN2 protein, which contains heparin 
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and integrin binding sites. These sites allow binding of CCN2 with heparin-sulfate-
containing-proteoglycans (e.g. perlecan 19) and cell surface integrin receptors (e.g. αvβ1 
and αvβ3 9-10) and could potentially induce different biological effects than the full-length 
CCN2 protein. This domain has been shown to have roles in cell adhesion, migration, 
angiogenesis and differentiation in other cell types 9,21–23. Interestingly, studies have 
shown have shown that CCN2 can be cleaved between domains 3 and 4, producing 
endogenous CCN2 fragments corresponding to the fourth domain. Studies performed in 
rat hepatic stellate 9 and pig uterine luminal flushings 24 demonstrated the presence of 
both full length CCN2 and the fragment corresponding to the fourth domain of CCN2. 
Therefore, determining the functional effects of module four of CCN2 on chordoma cell 
regulation is of importance. Future studies should compare the biological response of 
chordoma cells to the full-length rCCN2 or the fourth domain fragment of the protein. It 
should be noted that we also attempted to knock-down endogenous CCN2 expression in 
U-CH1 cells using shRNA to investigate the effects of the loss of CCN2. In all three 
experimental attempts to generate a stable CCN2 knockdown cell line, we noted 
increased cell apoptosis and a loss of cell adhesion, preventing cell expansion and 
experimentation. To complement the gain-of-function experiments presented in the 
current study, future experiments could attempt to generate CCN2-depleted U-CH1 cells 
using inducible shRNA constructs to permit the creation of a stable transgenic cell line 
prior to CCN2 knockdown.  
 
 Another limitation of our study is the use of in vitro experiments, which makes it 
difficult to determine the effect of the entire tumor microenvironment. Future studies 
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should examine the effects of CCN2 using in vivo mouse xenograft models 
overexpressing CCN2 in U-CH1 cells to investigate the effects of the complete tumor 
microenvironment on the regulation of human chordoma cells. In addition, it may be 
worthwhile examining the effects of other CCN matricellular proteins, as we detected the 
expression of CCN1, CCN2, CCN3 and CCN5 in U-CH1 cells with an increase in CCN3 
and CCN5 in response to hypoxia. To our knowledge, there are currently no studies that 
investigate the role of CCN proteins in chordomas, which have all been shown to regulate 
cancer properties including cell proliferation 18-19, metastasis 27 and migration 28. 
Additionally, studies have shown increased expression of CCN proteins under hypoxia 
compared to normoxia, such as increases in CCN1 and CCN3 in human choriocarcinoma 
cells 29 and CCN1 in retinal vascular endothelial cells 30. This suggests and CCN5 may be 
involved in the increased progenitor-like properties we see under hypoxia. Furthermore, 
we also found increased expression of CCN1, CCN3 and CCN5 following treatment of U-
CH1 cells with rCCN2domain4 under normoxia and hypoxia. We suggest that future studies 
focus on investigating the effects of these CCN members on U-CH1 cells and 
determining the mechanisms through which CCN2 regulates the expression of other CCN 
family members. 
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8.3 The licensing transaction described in the Order Confirmation is personal to User. Therefore, User may not assign or 
transfer to any other person (whether a natural person or an organization of any kind) the license created by the Order 
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Confirmation and these terms and conditions or any rights granted hereunder; provided, however, that User may assign 
such license in its entirety on written notice to CCC in the event of a transfer of all or substantially all of User’s rights in 
the new material which includes the Work(s) licensed under this Service.
8.4 No amendment or waiver of any terms is binding unless set forth in writing and signed by the parties. The 
Rightsholder and CCC hereby object to any terms contained in any writing prepared by the User or its principals, 
employees, agents or affiliates and purporting to govern or otherwise relate to the licensing transaction described in the 
Order Confirmation, which terms are in any way inconsistent with any terms set forth in the Order Confirmation and/or in 
these terms and conditions or CCC's standard operating procedures, whether such writing is prepared prior to, 
simultaneously with or subsequent to the Order Confirmation, and whether such writing appears on a copy of the Order 
Confirmation or in a separate instrument.
8.5 The licensing transaction described in the Order Confirmation document shall be governed by and construed under 
the law of the State of New York, USA, without regard to the principles thereof of conflicts of law. Any case, controversy, 
suit, action, or proceeding arising out of, in connection with, or related to such licensing transaction shall be brought, at 
CCC's sole discretion, in any federal or state court located in the County of New York, State of New York, USA, or in any 
federal or state court whose geographical jurisdiction covers the location of the Rightsholder set forth in the Order 
Confirmation. The parties expressly submit to the personal jurisdiction and venue of each such federal or state court.If 
you have any comments or questions about the Service or Copyright Clearance Center, please contact us at 978-750-
8400 or send an e-mail to info@copyright.com.
v 1.1
Close
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Curriculum Vitae 
Priya Patel  
 
University educational background: 
 
September 2012- July 2014     Masters in Anatomy and Cell Biology (M.Sc.) 
        Department of Anatomy and Cell Biology 
        University of Western Ontario (Western), London, ON 
 
September 2008- April 2012     Honours Bachelor of Medical Sciences (B.M.Sc.) 
         University of Western Ontario (Western), London, ON 
 
Honours and awards: 
 
1) Ontario Graduate Scholarship (September 2013- August 2014)- $15,000 
 
2) Poster presentation award at Canadian Connective Tissue Conference (June 2013)- 
$300 
 
3) Canadian Institutes of Health Research (CIHR) Master’s Award: Fredrick Banting and 
Charles Best Canada Graduate Scholarship (September 2012- August 2013)- $17,500 
 
4) Ontario Graduate Scholarship (September 2012- August 2013)- declined- $15,000 
 
5) Western Graduate Scholarship (September 2012- August 2014)- $9,000 
 
6) Member of Dean’s Honour Roll (2008-2012) 
 
7) Western Scholar Distinction (2009-2012) 
 
8) CIHR Summer Undergraduate Award in Mobility, Musculoskeletal Health and 
Arthritis (May- August 2012) - $4,950 
 
9) Canadian Red Cross Volunteer Appreciation Award (2011-2012) 
 
10) CIHR Summer Undergraduate Award in Mobility, Musculoskeletal Health and 
Arthritis (May- August 2011)- $4,950 
11) CIHR Joint Motion Program’s Summer Undergraduate Studentship Award (May- 
August 2011)- $1,050 
 
12) Canadian Red Cross Volunteer Appreciation Award (2009-2010) 
 
13) Western Scholarship of Distinction (2008)- $1,000 
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Related work experience: 
 
Supervisory Experience 
1. Gurkeet Lalli, 4th year undergraduate thesis student 
 September 2013- April 2014 
 Project entitled: The effects of whole body vibration on joint health 
 Dr. Cheryle Séguin’s Lab, University of Western Ontario, London, ON 
 
2.  Michael Barblinardo, 1st year dentistry student 
 May-August 2012 
 Project entitled: The effects of chronic vibration on the intervertebral discs. 
 Dr. Cheryle Séguin’s Lab, University of Western Ontario, London, ON 
 
Teaching Assistant          September 2012- February 2013 
Department of Anatomy and Cell Biology, University of Western Ontario 
• Facilitated weekly gross anatomy (Anatomy 9501) lab sessions for first-year 
physiotherapy students by utilizing cadavers for dissections and anatomical 
prossections 
• Proctored and evaluated course examinations 
 
Undergraduate Research Student           May 2011- August 2012 
Dr. Cheryle Séguin, Department of Physiology and Pharmacology, University of Western 
Ontario 
• Investigated the effects of whole-body vibration platforms on intervertebral discs of 
the spinal column using ex vivo and in vivo mice models 
 
Undergraduate Research Student         May 2010- January 2011 
Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto  
• Examined the use of total quality culture management in staffing models for both 
national and international hospitals and radiation therapy departments  
• Investigated the effects of whole brain radiation therapy in the treatment of multiple 
brain metastases for a novel patient case 
 
Publications: 
 
1. McCann MR, Patel P, Pest M, Ratneswaran A, Kamphuis M, Esmail Z, Lee J, 
 Barbilinardo M, Beaucage K, Holdsworth DW, Beier F, Dixon SJ, Séguin  CA. 
 Repeated exposure to high-frequency low-amplitude vibration induces 
 degeneration of intervertebral disc and knee joints in a murine model. (In-
 preparation for submission to Arthritis and Rheumatology) 
2.  Matthew R. McCann, Priya Patel, Yizhi Xiao, Walter L. Siqueira, Cheryle A. 
 Séguin. Proteomic Signature of the Murine Intervertebral Disc. (Submitted to 
 PLOS One June 2014) 
3. Matthew R. McCann*, Priya Patel*, Kim L. Beaucage, Yizhi Xiao, Corey 
 Bacher, Walter L. Siqueira, David W. Holdsworth, S. Jeffrey Dixon, Cheryle A. 
 Séguin. Acute vibration induces transient expression of anabolic genes in the 
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 murine intervertebral disc. (Arthritis & Rheumatism 2013 July; 65(7): 1853-
 1864.) *equal first-author contribution  
4.  Patel P, Mitera G. A Systematic Scoping Literature Review of Incorporating a 
 Total Quality  Culture Within Radiotherapy Staffing Models: A Management 
 Strategy to Improve Patient Safety and Quality of Care in Radiation Therapy 
 Departments. (Journal of Medical Imaging and Radiation Sciences 2011 
 June;42(2):81-85.)   
5.  Patel P, Mitera G. Management of symptomatic brain metastases. (Radiation  
 Therapist 2011 March;20(1):81-84.)  
 
Oral presentations 
*equals presenting author at conference 
1.  Matthew R. McCann*, Priya Patel, Michael Barbalinardo, Michael A. Pest, Kim 
 L. Beaucage,  Meg P. Kamphuis, Frank Beier, David W. Holdsworth, S. Jeffrey 
 Dixon, Cheryle A. Séguin. Repeated daily exposure to high-frequency low-
 amplitude vibration negatively affects cartilaginous joints. London Health 
 Research Day: March 9, 2013, London, Ontario, Canada.  
2.  McCann MR*, Patel P, Beaucage KL, Bacher C, Nikolov N, Pollmann SI, 
 Holdsworth DW, Dixon SJ, Séguin CA. Acute vibration induces transient 
 expression of anabolic genes in the intervertebral disc in a frequency dependent 
 manner. London Health Research Day: March 20, 2012, London, Ontario, 
 Canada.  
 
Poster presentations 
*equals presenting author at conference 
1.  Priya Patel, Courtney Brooks, Dr. Cheryle A. Séguin. Investigating 
 microenvironmental regulation of human chordoma cell behaviour. London 
 Health Research Day: March 18, 2014, London, Ontario, Canada.  
2. Priya Patel*, Courtney Brooks, Cheryle A. Séguin. Investigating the expression 
 of matricellular proteins in human chordoma. Spine Research Symposium: 
 November 6-8, 2013, Philadelphia, Pennsylvania, U.S.A.  
3.  Priya Patel*, Courtney Brooks, Cheryle A. Séguin. Investigating the expression 
 of matricellular proteins in human chordoma. The Annual Anatomy and Cell 
 Biology Research Day: November 24, 2013, University of Western Ontario, 
 London, Ontario, Canada.  
4.  Priya Patel*, Matthew R. McCann, Kim L. Beaucage, Yizhi Xiao, Corey Bacher, 
 Walter L. Siqueira, David W. Holdsworth, S. Jeffrey Dixon, Cheryle A. Séguin. 
 Acute exposure to whole body vibration significantly alters intervertebral disc 
 homeostasis. Canadian Connective Tissue Conference: May 29-June 1, 2013, 
 Montreal, Quebec, Canada. (Awarded 1st place for poster presentation) 
5.  Patel P*, McCann MR, Beaucage KL, Bacher C, Nikolov N, Pollmann SI, 
 Holdsworth DW, Dixon SJ, Séguin CA. Acute vibration induces transient 
 expression of anabolic genes in the intervertebral disc in a frequency dependent 
 manner. Annual Bone and Joint Retreat: May 8 2013, University of Western 
 Ontario, London, Ontario, Canada.  
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6.  Matthew R. McCann*, Priya Patel, Michael Barbalinardo, Michael A. Pest, Kim 
 L. Beaucage,  Meg P. Kamphuis, Frank Beier, David W. Holdsworth, S. Jeffrey 
 Dixon, Cheryle A. Séguin. Repeated daily exposure to high-frequency low-
 amplitude vibration negatively affects articular joints. Gordon Research 
 Conference on Cartilage Biology and Pathology: April 7-12, 2013, Les 
 Diablerets, Switzerland. 
7.  P. Patel*, M.R. McCann, K.L. Beaucage, H. N. Nikolov, S.I. Pollmann, W.L. 
 Siqueira, D.W. Holdsworth, S.J.Dixon, C.A. Séguin. Acute exposure to whole 
 body vibration significantly  alters intervertebral disc homeostasis in a 
 frequency-dependent manner. London Health Research Day: March 19, 2013, 
 London, Ontario, Canada.  
8.  McCann MR*, Patel P, Beaucage KL, Bacher C, Nikolov N, Pollmann SI, 
 Holdsworth DW, Dixon SJ, Séguin CA. Acute vibration induces transient 
 expression of anabolic genes in the intervertebral disc in a frequency dependent 
 manner. The Annual Physiology and  Pharmacology Research Day: November 6, 
 2012, University of Western Ontario, London, Ontario, Canada.  
9.  Patel P*, McCann MR, Beaucage KL, Bacher C, Nikolov N, Pollmann SI, 
 Holdsworth DW, Dixon SJ, Séguin CA. Acute vibration induces transient 
 expression of anabolic genes in the intervertebral disc in a frequency dependent 
 manner. The Annual Anatomy and Cell Biology Research Day: October 25, 2012, 
 University of Western Ontario, London, Ontario, Canada. 
10. Patel P*, McCann MR, Beaucage KL, Bacher C, Nikolov N, Pollmann SI, 
 Holdsworth DW, Dixon SJ, Séguin CA. Acute vibration induces transient 
 expression of anabolic genes in the intervertebral disc in a frequency dependent 
 manner. Canadian Connective Tissue Conference: June 8-10, 2012, Toronto, 
 Ontario, Canada.  
11.  McCann MR*, Patel P, Beaucage KL, Bacher C, Nikolov N, Pollmann SI, 
 Holdsworth DW, Dixon SJ, Séguin CA. Effect of vibration on intervertebral disc 
 homeostasis in a mouse model. Spine Research Symposium: November 16-18,  
 2011, Philadelphia, Pennsylvania, U.S.A.  
12.  McCann MR*, Patel P, Beaucage KL, Bacher C, Nikolov N, Pollmann SI, 
 Holdsworth DW, Dixon SJ, Séguin CA. Effect of vibration on intervertebral disc 
 homeostasis in a mouse model. Canadian Arthritis Network Annual Scientific 
 Conference: October 27-29, 2011, Quebec City, Quebec, Canada.  
13.  Patel P*, McCann MR, Beaucage KL, Bacher C, Nikolov N, Pollmann SI, 
 Holdsworth DW, Dixon SJ, Séguin CA. Modulating intervertebral disc 
 homeostasis through vibration. Annual CIHR Joint Motion Program Summer 
 Research Symposium: August 4, 2011, London, Ontario, Canada. 
 
 
 
 
